Loading Events

Events

« All Events

  • This event has passed.

BIRD Foundation Lunch & Learn

July 1


Learn about important non-dilutive funding opportunities for technology companies
July 1, 2021  |  12:00 pm – 1:00 pm EST
 
A Virtual Conversation
BIRD Foundation Lunch & Learn
 
Learn about important non-dilutive funding opportunities for technology companies
 
Join us on July 1 for a live virtual event on a unique funding opportunity for joint collaborations between U.S. companies in our region and companies in Israel. Annually, BIRD approves 20-25 grants of up to a $1 million (with the potential for up to $1.5 million for exceptional proposals) for the co-development of innovative products, technologies or milestone-based pharma projects. BIRD takes no IP or equity.
 
The virtual event is co-hosted by the Philadelphia-Israel Chamber of Commerce, the US-Israel Binational Industrial Research and Development (BIRD) Foundation in Pennsylvania, Delaware and Southern New Jersey, the World Trade Center Delaware and the Delaware BioScience Association.
 
BIRD’s scope extends to Advanced Manufacturing, Agrotechnology, Cleantech and Environment, Communications, Construction Tech, Electronics, FinTech, Gas, Healthcare IT, Homeland Security and Cyber Security, Life Sciences and Bio-Convergence, Software, Water and Wastewater technologies, etc. and other technology sectors.
 
A meeting link will be provided after you register!

 


PROGRAM:

World Trade Center Delaware and Delaware Bio Introduction Remark
Carla Stone, President, World Trade Center Delaware
Michael Fleming, President, Delaware BioScience Association

Why Israel?
Vered Nohi, Executive Director, Philadelphia-Israel Chamber of Commerce and Representative for PA, DE and SNJ, BIRD Foundation

BIRD Foundation Funding Opportunity
Andrea Yonah, Director of Business Development, East Coast & Midwest, BIRD Foundation

Delaware Based BIRD Project Case Study: The Gene Editing Institute of Christiana Care Health System’s Helen F. Graham Cancer Center & Research Institute was awarded a $900,000 grant with Israeli biotechnology company Fore Biotherapeutics, formally known as NovellusDx. The companies co-developed new gene editing technologies that help identify the genetic mechanism responsible for both the onset and progression of many types of cancer.
Eric B.Kmiec, Ph.D., Director, Gene Editing Institute, Christiana Care | Helen F. Graham Cancer Center & Research Institute

Q&A

Conclusion

 

Details

Date:
July 1